Dramatic Response to Hormone Therapy Plus CDK4/6 Inhibitor of a Retinal Detachment Secondary to Luminal Advanced Breast Cancer
Received Date: Apr 23, 2021 / Accepted Date: May 07, 2021 / Published Date: May 14, 2021
Abstract
Luminal breast cancer is hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive) and human epidermal growth factor receptor 2-negative (HER2-). Currently, the standard treatment of luminal metastatic breast cancer is the combination of hormone therapy with CDK4/6 (Cyclin-Dependent Kinases 4/6) inhibitors. The overall response rates for the combination are between 40% to 50%, increasing Progression Free Survival (PFS) and Overall Survival (OS) compared with hormone therapy alone. Herein, we report a clinical case showing the management of a patient with luminal breast cancer in different stages of the disease, highlighting the dramatic response of cyclin inhibitor plus fulvestrant to a bilateral retinal detachment due to ocular metastases.
Keywords: Luminal breast cancer, Hormone Therapy, CDK4/6 inhibitor, Carcinoma, Meningioma
Citation: Abad MN, Salvador MO, Fariñas SC, Hernández JM, Navarro VC et al. (2021) Dramatic Response to Hormone Therapy Plus CDK4/6 Inhibitor of a Retinal Detachment Secondary to Luminal Advanced Breast Cancer. J Clin Exp Pathol 11: 399.
Copyright: © 2021 Abad MN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 1595
- [From(publication date): 0-2021 - Aug 16, 2024]
- Breakdown by view type
- HTML page views: 1170
- PDF downloads: 425
